Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose nearly 3% towards the end of trading, currently up 2.04% at HKD 7.51, with a trading volume of HKD 408 million [1] Group 1: Clinical Application Approval - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has received acceptance for the clinical application of Beipiduo Acid Tablets, classified as a Class 3 chemical drug by the China National Medical Products Administration (NMPA) [1] - Beipiduo Acid is an ATP-citrate lyase inhibitor primarily used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients who cannot tolerate statin therapy, reducing the risk of myocardial infarction and coronary artery revascularization [1] Group 2: Market Potential - Beipiduo Acid was first approved for marketing by the FDA in the United States in 2020, and market analysts estimate that it could capture up to 25% of the cholesterol medication market, with peak sales expected to reach between USD 2 billion to USD 3 billion [1] - Currently, no original or generic versions of Beipiduo Acid have been launched in the domestic market, but four companies, including CSPC Ouyi Pharmaceutical, have had their clinical applications accepted, indicating the start of a competition for the first generic version [1]
石药集团尾盘涨近3% 贝派度酸片临床申请获受理 入局全新“非他汀类”降脂药